Analysis
Oura Health filed its S-1 with the SEC on September 3, confirming a Nasdaq listing under the ticker OURA and disclosing financials that are unusual for 2026's IPO class in one specific way: the company is actually profitable. Revenue reached $1.21 billion for the nine months ended June 30, up 74% from a year earlier, and the Finnish-founded, San Francisco-headquartered ring maker posted a real net profit on more than a billion dollars of trailing revenue.
Oura has not yet set a share count or price range, but Bloomberg reported the listing could value the company north of $16 billion, on a raise of up to $3 billion -- a target that would make it one of 2026's largest consumer-hardware listings regardless of how the AI megadeals resolve.
Oura's story has been a decade-long build: the company started as a Finnish hardware startup making a health-tracking ring, went through several product iterations that flopped commercially, and only became a mainstream category leader in the last three to four years as investors and consumers converged on wearables that track sleep and recovery rather than just steps. That patience is now showing up in the numbers -- 5 million paid members, each generating recurring subscription revenue on top of the hardware sale, which is the metric that turns a device company into something bankers can underwrite like a software business.
“## The competitive set, and why the multiple matters Oura's closest public comparables are thinner than they look.”
The competitive set, and why the multiple matters
Oura's closest public comparables are thinner than they look. Garmin sells wearables but at far lower margins and without Oura's subscription attach rate; Apple Watch and Whoop are the two most-cited private rivals, with Whoop still private and unprofitable by most outside estimates. That scarcity of a clean public comp is exactly why the ~11-12x trailing-revenue multiple implied by a $16 billion valuation on $1.4 billion of revenue matters beyond Oura itself -- it becomes the reference point every consumer-hardware-with-subscription startup will get valued against for the next several quarters, the way Peloton's multiple did in 2019 before its own numbers went the other direction.
- Oura -- $1.21B 9-month revenue (+74% YoY), $59M net profit, 5M paid members: Nasdaq listing under OURA, banks led by Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Company and Jefferies. Founded in Finland, HQ San Francisco.
- Whoop -- private, unprofitable by most outside estimates: closest direct wearables competitor, no public financials to compare against Oura's disclosed numbers.
- Garmin -- public, lower-margin hardware model: sells wearables without Oura's subscription-revenue attach rate, making it a weaker comp for the multiple bankers will pitch.
Pulse has covered the broader IPO pipeline bottleneck this month -- OpenAI, Anthropic, SpaceX and Canva are all facing pressure to prove business models durable enough for a public listing, and a New York Times report from June indicated OpenAI is now leaning toward 2027 rather than 2026 over valuation concerns. Oura filing cleanly with a five-name underwriting syndicate this month is itself informative: it suggests there is still real banking capacity for a well-understood consumer story, even as the AI megadeals absorb attention and staffing further up the pipeline. The 2026 IPO market overall has logged 238 listings as of September 7, a modest 2.15% ahead of the 233 recorded by the same point in 2025 -- growth, but not the surge the AI-IPO narrative implies.
The risk sitting underneath the profitable growth story is straightforward: wearables are a hit-driven hardware category, and Oura's 74% growth rate has to hold up against Apple, Samsung and a wave of cheaper ring competitors entering the category behind it, none of which currently disclose the kind of subscription attach and retention numbers that would let outside investors stress-test whether 5 million paid members is a durable base or a peak. A single bad product cycle -- the kind that hit Fitbit, GoPro and Peloton in turn -- would test the multiple bankers are currently pitching far faster than a software company's would be tested.
What happens to Oura's roadshow reception over the next several weeks will tell underwriters whether investors are still willing to pay a software-like multiple for a hardware company with genuine subscription economics, at a moment when most of the market's attention is fixed on the much larger AI-lab listings still waiting behind it in the queue.
